Project Grant R01HL181348
Award Date 9/23/25
Completion Date 8/31/27
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award of $153,099.00 from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) is funding research to use target trial emulation and g-methods for causal inference from observational data to address gaps in knowledge about the care of patients with acute respiratory distress syndrome (ARDS), with a focus on evaluating dynamic treatment regimes for steroid initiation, duration, and dosing. The research will utilize data...
- This federal Project Grant award, titled "RESILIENCE ENDOTYPE-DERIVATION THROUGH PARSIMONIOUS ANALYSIS AND CAUSAL INFERENCE OF RECOVERY FROM ACUTE RESPIRATORY DISTRESS SYNDROME (REPAIR-ARDS)", is funded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) in the amount of $674,351. The project aims to develop predictive models for early diagnosis of Acute Respiratory Distress Syndrome (ARDS) using protein biomarkers and clinical data, as...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $737,815 to The Washington University in St. Louis to develop and validate an automated electronic health record (EHR)-embedded system that can classify molecular phenotypes of acute respiratory distress syndrome (ARDS) and sepsis at the bedside. The primary objective is to translate advanced research on ARDS and sepsis heterogeneity into clinical...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
- This federal Project Grant award of $200,502 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project led by Dr. Narges Alipanah-Lechner at the University of California, San Francisco (UCSF). The project aims to identify metabolite and protein drivers of the evolution of Acute Respiratory Distress Syndrome (ARDS) subtypes, specifically the hyper-inflammatory and hypo-inflammatory forms. The research will utilize comprehensive...
- This $247,500 project grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to develop a non-invasive model for early detection of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS). The research aims to leverage proteomic analysis of plasma samples from ARDS patient cohorts to derive and validate a classifier that can accurately identify PVD, a high-risk ARDS subgroup with...
- This $761,615 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of biological sex in the heterogeneity of Acute Respiratory Distress Syndrome (ARDS). The research team at Massachusetts General Hospital aims to determine how increased alveolar epithelial expression of Secretory Leukocyte Protease Inhibitor (SLPI) in females may increase epithelial glycocalyx resilience, leading to a...
- This $437,250 project grant, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to improve the characterization of individualized treatment effects in critical illness, particularly for sepsis and acute respiratory distress syndrome (ARDS). The research will focus on developing computational approaches to estimate individualized treatment effects (ITEs) using machine learning, which can uncover...
- This federal Project Grant award of $169,344 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to advance the management of critically ill adults with non-ARDS acute hypoxemic respiratory failure (NAHRF). The key objectives are to: 1) Develop clinical prediction models for mortality in NAHRF patients; 2) Apply machine learning to detect NAHRF subphenotypes associated with differential clinical outcomes; and 3) Use sequencing-based whole...